HHTU News Roundup

Productive month in the STARLIT programme of work

January has been a productive month across all three STARLIT studies. The STARLIT (Salivary Test for Adrenal Response to Liquid Intranasal Tetracosactide) programme aims to develop and clinically validate a new needle-free test (the Nasacthin Test) for the diagnosis of adrenal insufficiency.

In STARLIT 1, which looked at the repeatability of blood and saliva cortisol and cortisone levels within the same individual when samples were taken close together, had the final study report submitted to the Research Ethics Committee.

The protocol paper for the follow-on study, STARLIT 2, was published in BMJ Open. The STARLIT-2 study is a healthy volunteer study which is looking to see if the new Nasacthin Test (drug given via a nasal spray and cortisol and cortisone levels measured in saliva) gives comparable results to the standard test, the Short Synacthen Test (drug given using a needle and cortisol measured in blood samples).

Finally, STARLIT 3, which will test the effectiveness of the Nasacthin Test in patients with adrenal insufficiency received sponsor regulatory green light, so is ready to open the study sites to recruitment.

Click here for more information about STARLIT.

PRE-DX has 2 abstracts accepted

The PRE-DX study had abstracts accepted for to the19th St. Gallen International Breast Cancer Conference 2025 in Austria in March and the Association of Breast Surgery (ABS) conference in May.  The abstract for St Gallen is for a poster presentation and the ABS abstract is for an oral presentation and both will be the first dissemination of the study results. 

Other project headlines:

---

---

---

---

---